You are here: Industry Insights > Lilly

News List

Lilly’s combo therapy succeeds in the late-stage lung cancer study expressbpd
March 19, 2019
Previously untreated patients with metastatic non-small cell lung cancer taking a combination of Lilly’s Cyramza and Roche’s erlotinib went longer before their disease started to worsen
Now that Lilly has a cheaper generic Humalog, will Novo Nordisk and Sanofi follow? fiercepharma
March 08, 2019
Caught by an outcry over high insulin prices, Eli Lilly recently unveiled an authorized generic version of its Humalog insulin at half the price of the original brand.
Lilly to sell generic Humalog insulin at half price pharmaphorum
March 07, 2019
Eli Lilly has responded to criticism of high prices for insulin products in the US by launching a cut-price version of its Humalog brand.
Lilly claims fast FDA review for Emgality in cluster headache pharmaphorum
March 07, 2019
Eli Lilly has a battle on its hands in the migraine prevention category with third-to-market CGRP inhibitor Emgality but could get a leg-up with an indication in episodic cluster headache.
Lilly introduces cheaper generic insulin in the US europeanpharmaceuticalreview
March 06, 2019
The generic version will cost 50 percent less that the current Humalog list price…
More positive results for Pfizer/Lilly’s non-opioid pain drug pharmaphorum
February 22, 2019
Pfizer and Eli Lilly have announced more positive results from a phase 3 study of their non-opioid pain drug tanezumab, this time in chronic lower back pain (CBLP).
Pfizer, Lilly Announce Top-line Results from Tanezumab Phase 3 Study americanpharmaceuticalreview
February 20, 2019
Pfizer and Eli Lilly and Company announced positive top-line results from a Phase 3 study evaluating tanezumab in patients with moderate-to-severe chronic low back pain (CLBP)....
Lilly Announces Top-Line Phase 3 Results for Baricitinib Trial americanpharmaceuticalreview
February 19, 2019
Eli Lilly and Company and Incyte announced baricitinib met the primary endpoint in BREEZE-AD1 and BREEZE-AD2, two Phase 3 studies evaluating the efficacy and safety of baricitinib monotherapy for the treatment of adult patients with ....
Lilly closes $8bn Loxo Oncology acquisition pharmaceutical-technology
February 19, 2019
Eli Lilly has completed the acquisition of all outstanding shares of Loxo Oncology in a deal valued at approximately $8bn, boosting its oncology portfolio with precision medicines to potentially treat genomically defined cancers.
Lilly asks migraine patients to use their imaginations in first DTC push for Emgality fiercepharma
February 18, 2019
Eli Lilly’s first effort for migraine drug Emgality had a personal connection for the director of the TV commercial.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 25 26 Next page